ZA200908882B - Sirtuin modulating imidazothiazole compounds - Google Patents

Sirtuin modulating imidazothiazole compounds

Info

Publication number
ZA200908882B
ZA200908882B ZA200908882A ZA200908882A ZA200908882B ZA 200908882 B ZA200908882 B ZA 200908882B ZA 200908882 A ZA200908882 A ZA 200908882A ZA 200908882 A ZA200908882 A ZA 200908882A ZA 200908882 B ZA200908882 B ZA 200908882B
Authority
ZA
South Africa
Prior art keywords
sirtuin modulating
imidazothiazole compounds
imidazothiazole
compounds
sirtuin
Prior art date
Application number
ZA200908882A
Other languages
English (en)
Inventor
Jean Bemis
Jeremy S Disch
Michael Jirousek
Walter Joseph Lunsmann
Pui Yee Ng
Chi B Vu
Original Assignee
Sirtris Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39810276&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200908882(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sirtris Pharmaceuticals Inc filed Critical Sirtris Pharmaceuticals Inc
Publication of ZA200908882B publication Critical patent/ZA200908882B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ZA200908882A 2007-06-20 2009-12-14 Sirtuin modulating imidazothiazole compounds ZA200908882B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US93663307P 2007-06-20 2007-06-20

Publications (1)

Publication Number Publication Date
ZA200908882B true ZA200908882B (en) 2010-08-25

Family

ID=39810276

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200908882A ZA200908882B (en) 2007-06-20 2009-12-14 Sirtuin modulating imidazothiazole compounds

Country Status (26)

Country Link
US (2) US7829556B2 (enExample)
EP (1) EP2167510B1 (enExample)
JP (1) JP5281081B2 (enExample)
KR (1) KR101525268B1 (enExample)
CN (1) CN101874031B (enExample)
AR (1) AR067106A1 (enExample)
AU (1) AU2008266746B2 (enExample)
BR (1) BRPI0813653A2 (enExample)
CA (1) CA2692099C (enExample)
CL (1) CL2008001821A1 (enExample)
CO (1) CO6261382A2 (enExample)
CR (1) CR11231A (enExample)
DO (1) DOP2009000283A (enExample)
EA (1) EA018182B1 (enExample)
ES (1) ES2534544T3 (enExample)
IL (1) IL202729A (enExample)
MA (1) MA31568B1 (enExample)
MX (1) MX2009013976A (enExample)
MY (1) MY149316A (enExample)
NZ (1) NZ581989A (enExample)
PE (1) PE20090423A1 (enExample)
TW (1) TW200918542A (enExample)
UA (1) UA104127C2 (enExample)
UY (1) UY31170A1 (enExample)
WO (1) WO2008156866A1 (enExample)
ZA (1) ZA200908882B (enExample)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
US11207518B2 (en) 2004-12-27 2021-12-28 The Feinstein Institutes For Medical Research Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
EP1853610A1 (en) * 2005-03-03 2007-11-14 Sirtris Pharmaceuticals, Inc. N-phenyl benzamide derivatives as sirtuin modulators
ES2397275T3 (es) 2005-08-04 2013-03-05 Sirtris Pharmaceuticals, Inc. Derivados de imidazopiridina como agentes moduladores de la sirtuína
US20070077310A1 (en) * 2005-10-03 2007-04-05 University Of Tennessee Research Foundation Methods of reducing the production of reactive oxygen species and methods of screening or identifying compounds and compositions that reduce the production of reactive oxygen species
TW200918542A (en) * 2007-06-20 2009-05-01 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
CL2008001822A1 (es) * 2007-06-20 2009-03-13 Sirtris Pharmaceuticals Inc Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras.
US8391970B2 (en) * 2007-08-27 2013-03-05 The Feinstein Institute For Medical Research Devices and methods for inhibiting granulocyte activation by neural stimulation
US20120156134A1 (en) 2007-12-20 2012-06-21 Shayne Squires Compositions and methods for detecting or eliminating senescent cells to diagnose or treat disease
WO2009099643A1 (en) * 2008-02-07 2009-08-13 The J. David Gladstone Institutes Use of sirt1 activators or inhibitors to modulate an immune response
US9662490B2 (en) 2008-03-31 2017-05-30 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
WO2009146030A1 (en) 2008-03-31 2009-12-03 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation of t-cell activity
EA021938B1 (ru) * 2008-05-01 2015-10-30 Сертрис Фармасьютикалз, Инк. Хинолины и их аналоги в качестве модуляторов сиртуина
CN104193740A (zh) 2008-07-03 2014-12-10 西特里斯药业公司 作为沉默调节蛋白调节剂的苯并咪唑类和相关的类似物
RU2519779C2 (ru) 2008-09-29 2014-06-20 Сертрис Фармасьютикалз Инк. Хиназолинон, хинолон и родственные аналоги в качестве модуляторов сиртуина
ES2452484T3 (es) 2008-11-18 2014-04-01 Setpoint Medical Corporation Dispositivos para optimizar la colocación de electrodos para la estimulación antiinflamatoria
AU2009333588A1 (en) 2008-12-08 2011-07-21 Northwestern University Method of modulating HSF-1
CN102388054B (zh) 2008-12-19 2015-03-04 西特里斯药业公司 噻唑并吡啶沉默调节蛋白调节剂的化合物
US8996116B2 (en) * 2009-10-30 2015-03-31 Setpoint Medical Corporation Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
US9211410B2 (en) 2009-05-01 2015-12-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US20110054569A1 (en) * 2009-09-01 2011-03-03 Zitnik Ralph J Prescription pad for treatment of inflammatory disorders
CN102573986B (zh) 2009-06-09 2016-01-20 赛博恩特医疗器械公司 用于无导线刺激器的具有袋部的神经封套
JP2013509442A (ja) 2009-10-29 2013-03-14 サートリス ファーマシューティカルズ， インコーポレイテッド サーチュイン調節因子としての二環式ピリジンおよび類似体
EP2496594B1 (en) * 2009-11-06 2018-01-17 The J. David Gladstone Institutes Methods and compositions for modulating tau levels
US11051744B2 (en) 2009-11-17 2021-07-06 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
US9833621B2 (en) * 2011-09-23 2017-12-05 Setpoint Medical Corporation Modulation of sirtuins by vagus nerve stimulation
WO2011079309A2 (en) 2009-12-23 2011-06-30 Setpoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
JP6038773B2 (ja) 2010-04-15 2016-12-07 サートリス ファーマシューティカルズ， インコーポレイテッド サーチュイン活性化因子および活性化アッセイ
CN107988228B (zh) * 2010-05-03 2022-01-25 库尔纳公司 通过抑制沉默调节蛋白(sirt)的天然反义转录物而治疗沉默调节蛋白(sirt)相关疾病
WO2011143317A2 (en) * 2010-05-11 2011-11-17 President And Fellows Of Harvard College Methods for the regulation of cellular metabolism through the modulation of sirt3 activity
DK2670404T3 (en) 2011-02-02 2018-11-19 Univ Princeton CIRCUIT MODULATORS AS VIRUS PRODUCTION MODULATORS
US12172017B2 (en) 2011-05-09 2024-12-24 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
EP2707094B1 (en) 2011-05-09 2016-02-03 Setpoint Medical Corporation Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
WO2012177927A1 (en) 2011-06-21 2012-12-27 Mayo Foundation For Medical Education And Research Transgenic animals capable of being induced to delete senescent cells
RU2631597C2 (ru) 2011-07-15 2017-09-25 Нусерт Сайенсиз, Инк. Композиции и способы модулирования метаболических путей
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CA2859385A1 (en) 2011-12-13 2013-06-20 Buck Institute For Research On Aging Methods for improving medical therapies
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
US9572983B2 (en) 2012-03-26 2017-02-21 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
WO2013158664A2 (en) 2012-04-17 2013-10-24 Kythera Biopharmaceuticals, Inc. Use of engineered viruses to specifically kill senescent cells
US9901081B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse for determining the role of senescent cells in cancer
US9901080B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells
CN108452311A (zh) 2012-11-13 2018-08-28 纽斯尔特科学公司 用于增强能量代谢的组合物和方法
EP2968333B1 (en) 2013-03-15 2022-01-12 NuSirt Sciences, Inc. Leucine and nicotinic acid for the reduction of lipid levels
WO2015002892A1 (en) * 2013-07-01 2015-01-08 Meier Joshua Abraham Methods of treating diseases by modulating mitochondrial dna deletions
SG11201607075TA (en) 2014-02-27 2016-09-29 Nusirt Sciences Inc Compositions and methods for the reduction or prevention of hepatic steatosis
JP2017518306A (ja) 2014-06-02 2017-07-06 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ 結晶性β−Ｄ−ニコチンアミドリボシドの製造および使用
KR20170008320A (ko) 2014-06-06 2017-01-23 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 니코틴아미드 리보시드 유사체 및 그의 제약 조성물 및 용도
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
WO2016126807A1 (en) 2015-02-03 2016-08-11 Setpoint Medical Corporation Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
KR101839688B1 (ko) 2015-08-21 2018-03-19 중앙대학교 산학협력단 이미다조티아졸 유도체 또는 이의 약학적으로 허용 가능한 염 및 이의 의약적 용도
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
WO2017123161A1 (en) * 2016-01-15 2017-07-20 Agency For Science, Technology And Research Inhibition of intracellular growth of mycobacterium species and its applications
EP3405107B1 (en) 2016-01-20 2023-04-12 Setpoint Medical Corporation Control of vagal stimulation
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
EP3405255A4 (en) 2016-01-20 2019-10-16 Setpoint Medical Corporation IMPLANTABLE MICROSTIMULATORS AND INDUCTIVE CHARGING SYSTEMS
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
CN109475572A (zh) 2016-02-22 2019-03-15 宾夕法尼亚州大学信托人 用于增强肝再生的方法
US11173307B2 (en) 2017-08-14 2021-11-16 Setpoint Medical Corporation Vagus nerve stimulation pre-screening test
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
CN109700790A (zh) * 2018-12-28 2019-05-03 中南大学湘雅医院 一种靶向AQP3的抗皮肤衰老药物Butein
CN113939334A (zh) 2019-04-12 2022-01-14 赛博恩特医疗器械公司 迷走神经刺激来处理神经退行性障碍
CN111000854B (zh) * 2019-12-30 2023-06-09 昆药集团股份有限公司 曲札茋苷在制备治疗和/或预防非酒精性脂肪肝病产品中的应用
KR20230012585A (ko) 2020-05-21 2023-01-26 더 파인스타인 인스티튜츠 포 메디칼 리서치 미주 신경 자극을 위한 시스템들 및 방법들
US12444497B2 (en) 2021-05-17 2025-10-14 Setpoint Medical Corporation Neurostimulation parameter authentication and expiration system for neurostimulation
KR20250039366A (ko) * 2022-06-17 2025-03-20 코다젠 바이오사이언시스 인코포레이티드 시르투인 활성화 화합물을 포함하는 시르투인 조절 화합물, 및 이의 응용
US12012370B1 (en) 2022-12-29 2024-06-18 Codagen Biosciences, Inc. Sirtuin modulating compounds and applications thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1108698B (de) 1959-09-03 1961-06-15 Hoechst Ag Verfahren zur Herstellung von 2-(2'-Aminoaryl)-4, 5-arylen-1, 2, 3-triazolen
US3517007A (en) 1968-04-05 1970-06-23 American Home Prod 5 - acetamido - 4 - pyrimidinecarboxamides,5 - acetamido - 4 - pyrimidinecarboxylic acid hydrazides and related compounds
ZA735753B (en) 1972-09-14 1974-07-31 American Cyanamid Co Resolution of 6-substituted amino phenyl-2,3,5,6-tetrahydro(2,1-b)thiadiazoles
US4018932A (en) 1975-11-03 1977-04-19 American Cyanamid Company Anthelmintic pour-on formulations for topical use on domestic and farm animals
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4939133A (en) 1985-10-01 1990-07-03 Warner-Lambert Company N-substituted-2-hydroxy-α-oxo-benzeneacetamides and pharmaceutical compositions having activity as modulators of the arachidonic acid cascade
JPH0576084A (ja) 1991-09-11 1993-03-26 Matsushita Electric Ind Co Ltd 遠隔表示装置
JPH05289689A (ja) 1992-04-06 1993-11-05 Sanyo Electric Co Ltd 可搬性規則音声合成装置
JPH07291976A (ja) 1994-04-27 1995-11-07 Otsuka Pharmaceut Factory Inc イミダゾ〔２，１−ｂ〕チアゾール誘導体
US6653309B1 (en) 1999-04-26 2003-11-25 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme technical field of the invention
DE19948434A1 (de) 1999-10-08 2001-06-07 Gruenenthal Gmbh Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine
CA2450555A1 (en) 2001-06-25 2003-01-03 Merck & Co., Inc. (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds
WO2003007959A1 (en) 2001-07-16 2003-01-30 Fujisawa Pharmaceutical Co., Ltd. Quinoxaline derivatives which have parp inhibitory action
US8354397B2 (en) 2001-07-27 2013-01-15 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
HUP0103986A2 (hu) 2001-09-28 2003-06-28 Richter Gedeon Vegyészeti Gyár Rt. Új karbonsavamid szerkezetet tartalmazó piperidinil vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0103987A3 (en) 2001-09-28 2004-11-29 Richter Gedeon Vegyeszet Phenylpiperazinylalkyl carboxylic acid amid derivatives, process for their preparation, pharmaceutical compositions containing them and their intermediates
JP2005298333A (ja) 2001-11-15 2005-10-27 Meiji Seika Kaisha Ltd 新規トリアゾール誘導体及びこれを有効成分とする抗真菌剤
DE602004015429D1 (de) 2003-03-11 2008-09-11 Pfizer Prod Inc Pyrazinverbindungen als inhibitoren des transforming growth factor (tgf)
EP1605967A1 (en) 2003-03-13 2005-12-21 Novo Nordisk A/S Novel nph insulin preparations
WO2005058884A2 (en) 2003-12-15 2005-06-30 Japan Tobacco Inc. Cyclopropane compounds and pharmaceutical use thereof
WO2005069998A2 (en) 2004-01-20 2005-08-04 Brigham Young University Technology Transfer Office Novel sirtuin activating compounds and methods for making the same
RU2445095C2 (ru) 2004-04-22 2012-03-20 Бёрингер Ингельхайм Интернациональ Гмбх Новые фармацевтические композиции для лечения сексуальных расстройств
AU2005257883A1 (en) * 2004-06-04 2006-01-05 Washington University Methods and compositions for treating neuropathies
EP1819341A4 (en) 2004-11-10 2011-06-29 Synta Pharmaceuticals Corp IL-12 MODULATORY CONNECTIONS
EP1853610A1 (en) 2005-03-03 2007-11-14 Sirtris Pharmaceuticals, Inc. N-phenyl benzamide derivatives as sirtuin modulators
BRPI0608910A2 (pt) 2005-05-09 2010-02-17 Achillion Pharmaceuticals Inc uso de um composto da fórmula ou um sal ou hidrato farmaceuticamente aceitável desse, composto ou sal ou hidrato do mesmo, composição farmacêutica e composição farmacêutica embalada
US7855289B2 (en) 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
ES2397275T3 (es) 2005-08-04 2013-03-05 Sirtris Pharmaceuticals, Inc. Derivados de imidazopiridina como agentes moduladores de la sirtuína
US8088928B2 (en) 2005-08-04 2012-01-03 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8093401B2 (en) 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
EA019951B1 (ru) 2007-03-01 2014-07-30 Новартис Аг Ингибиторы киназы pim и способы их применения
TW200918542A (en) 2007-06-20 2009-05-01 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
CL2008001822A1 (es) 2007-06-20 2009-03-13 Sirtris Pharmaceuticals Inc Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras.
CN101910184A (zh) 2007-11-08 2010-12-08 西特里斯药业公司 可溶性噻唑并吡啶
US20100168084A1 (en) 2008-05-08 2010-07-01 Huber L Julie Therapeutic compounds and related methods of use

Also Published As

Publication number Publication date
US8247565B2 (en) 2012-08-21
DOP2009000283A (es) 2011-03-31
CA2692099C (en) 2016-08-09
US20090012080A1 (en) 2009-01-08
KR20100038093A (ko) 2010-04-12
US20110015192A1 (en) 2011-01-20
CN101874031A (zh) 2010-10-27
AU2008266746B2 (en) 2012-03-15
AU2008266746A1 (en) 2008-12-24
BRPI0813653A2 (pt) 2014-12-30
TW200918542A (en) 2009-05-01
UY31170A1 (es) 2009-01-30
CL2008001821A1 (es) 2009-03-13
EA018182B1 (ru) 2013-06-28
EP2167510A1 (en) 2010-03-31
ES2534544T3 (es) 2015-04-24
IL202729A (en) 2013-10-31
WO2008156866A1 (en) 2008-12-24
CA2692099A1 (en) 2008-12-24
EA201070034A1 (ru) 2010-06-30
EP2167510B1 (en) 2015-02-25
NZ581989A (en) 2012-06-29
US7829556B2 (en) 2010-11-09
MA31568B1 (fr) 2010-08-02
IL202729A0 (en) 2010-06-30
CO6261382A2 (es) 2011-03-22
KR101525268B1 (ko) 2015-06-02
MY149316A (en) 2013-08-30
MX2009013976A (es) 2010-04-27
PE20090423A1 (es) 2009-04-18
JP2010530431A (ja) 2010-09-09
CN101874031B (zh) 2013-02-20
UA104127C2 (en) 2014-01-10
AR067106A1 (es) 2009-09-30
CR11231A (es) 2012-05-16
JP5281081B2 (ja) 2013-09-04

Similar Documents

Publication Publication Date Title
ZA200908882B (en) Sirtuin modulating imidazothiazole compounds
ZA200908883B (en) Sirtuin modulating compounds
IL213217A0 (en) Thiazolopyridine sirtuin modulating compounds
BRPI0819093A2 (pt) compostos moduladores de sirtuína
ZA201000255B (en) Substituted bicyclolactam compounds
IL200543A0 (en) Ppar active compounds
IL200548A0 (en) Ppar active compounds
EP2152081A4 (en) NEW CONNECTIONS
EP2146745A4 (en) NOVEL CONNECTIONS
GB0705882D0 (en) Novel compounds
GB0706630D0 (en) Novel compounds
GB0705803D0 (en) Novel compounds
GB0703973D0 (en) Novel compounds
HK1137997A (en) Sirtuin modulating imidazothiazole compounds
GB0700996D0 (en) Novel compounds
GB0704088D0 (en) Novel compounds
GB0700992D0 (en) Novel compounds
GB0701638D0 (en) Novel compounds
GB0703387D0 (en) Novel compounds
GB0703397D0 (en) Novel compounds
GB0703402D0 (en) Novel compounds
GB0703404D0 (en) Novel compounds
GB0703630D0 (en) Novel compounds
GB0703631D0 (en) Novel compounds
GB0703677D0 (en) Novel compounds